Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-056072
Filing Date
2025-06-03
Accepted
2025-06-03 18:46:56
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8805
  Complete submission text file 0001104659-25-056072.txt   10723
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filed by) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Subject) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-89990 | Film No.: 251021371
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)